Cell>Point, a company providing diagnostic imaging solutions, announced that it has completed the second phase of its three part clinical trial of 99mTc-EC-G. The latter promises to be used as a SPECT/CT imaging agent for diagnosing non-small cell lung cancer (NSCLC). Cell>Point is producing 99mTc-EC-G as a diagnostic imaging agent for cancer and cardiovascular conditions.
The second phase of the trial included comparing the efficacy and safety of administered 99mTc-EC-G, in addition to using a SPECT /CT camera to capture images with 18F-FDG contrast agent. Phase 2 trial was aiming to assess whether detecting NSCLC with 99mTc-EC-G and SPECT/CT is not going to be inferior to detecting NSCLC with 18F-FDG and PET/CT. David Rollo, M.D., Ph.D., Cell>Point president, said “We are very encouraged by the favorable trends observed in imaging the primary tumor in our Phase 2 study, and therefore have closed the trial,”